US HB3160 | 2023-2024 | 118th Congress
Status
Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on May 9 2023 - 25% progression
Action: 2023-05-12 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 9 2023 - 25% progression
Action: 2023-05-12 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.
Title
Pharmaceutical Research Transparency Act of 2023
Sponsors
Rep. Jamie Raskin [D-MD] | Rep. Elissa Slotkin [D-MI] |
History
Date | Chamber | Action |
---|---|---|
2023-05-12 | House | Referred to the Subcommittee on Health. |
2023-05-09 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2023-05-09 | House | Introduced in House |
Same As/Similar To
SB1476 (Same As) 2023-05-09 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/118th-congress/house-bill/3160/all-info |
Text | https://www.congress.gov/118/bills/hr3160/BILLS-118hr3160ih.pdf |